| Does atorvastatin induce aortic smooth muscle cell apoptosis in vivo? | |
| | |
MedLine Citation:
|
PMID: 20951229 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
It has been reported that HMG-CoA reductase inhibitors such as atorvastatin induce vascular smooth muscle cell (SMC) apoptosis in vitro. However, this effect remains to be demonstrated in vivo. The present studies were designed to test the ability of atorvastatin to induce SMC apoptosis in vivo, using the spontaneously hypertensive rat (SHR) as a well-known reference model of SMC apoptosis induction in vivo by cardiovascular drugs including the calcium channel blocker amlodipine. Atorvastatin was administered to SHR for 3 or 6weeks either alone or together with amlodipine, a drug combination clinically available to patients. Primary endpoints included aortic medial hypertrophy and aortic SMC hyperplasia, internucleosomal DNA fragmentation and expression of the apoptosis regulatory proteins Bax and Bcl-2. The SHR aorta showed no evidence of SMC apoptosis induction by atorvastatin, even at the high dose of 50mgkg(-1)day(-1), although the statin significantly reduced oxidative stress after 3weeks and blood pressure after 6weeks of administration. Amlodipine-induced regression of aortic hypertophy and aortic SMC hyperplasia were dose- and time-dependent, but there was no interaction between atorvastatin and amlodipine in modulating the primary endpoints. These results do not support the notion that atorvastatin induces SMC apoptosis in the aortic media in vivo. |
| | |
Authors:
|
Marielle Doyon; Taben Mary Hale; Julie-Emilie Huot-Marchand; Rong Wu; Jacques de Champlain; Denis Deblois |
Related Documents
:
|
15458979 - Differential expression patterns of proinflammatory and antiinflammatory mediators duri... 12530939 - Molecular mechanisms of angiotensin ii-induced vascular injury. 20721949 - A light-activated theranostic nanoagent for targeted macrophage ablation in inflammator... 18666849 - Influence of cd4+/cd25+ regulatory t cells on atherogenesis in patients with end-stage ... 17214579 - Viral anti-inflammatory reagents: the potential for treatment of arthritic and vasculit... 16596819 - Modulation of macrophage function and metabolism. 9248969 - Interactions among antibiotics, bacteria and the human immune system: the clinical rele... 21884169 - Rig-i-like receptors: cytoplasmic sensors for non-self rna. 19648269 - Tlr triggering on tolerogenic dendritic cells results in tlr2 up-regulation and a reduc... |
Publication Detail:
|
Type: Journal Article Date: 2010-10-14 |
Journal Detail:
|
Title: Vascular pharmacology Volume: 54 ISSN: 1879-3649 ISO Abbreviation: Vascul. Pharmacol. Publication Date: 2011 Jan-Feb |
Date Detail:
|
Created Date: 2011-03-16 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101130615 Medline TA: Vascul Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 5-12 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010. Published by Elsevier Inc. |
Affiliation:
|
Faculty of Pharmacy, Université de Montréal, 2900 Édouard-Montpetit, Room 3201, P.O. Box 6128, Station"Centre-Ville", Montréal, Québec, Canada, H3C 3J7. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Zoonotic Brugia pahangi filariasis in a suburbia of Kuala Lumpur City, Malaysia.
Next Document: Anti-arthritic effects of chlorogenic acid in interleukin-1?-induced rabbit chondrocytes and a rabbi...